Attributes | Values |
---|
rdf:type
| |
Description
| - To evaluate the efficancy and safety of dulanermin combined with paclitaxel and carboplatin and bevacizumab as first fine treatment for advanced or recurrent nonsmall cell lung cancer (NCLC). The study found that the addition of dulanermin to carboplatin and bevacizumab did not improve outcome in unselected patinets with previously untreated advanced or recurrent NSCLC
- To evaluate the efficancy and safety of dulanermin combined with paclitaxel and carboplatin and bevacizumab as first fine treatment for advanced or recurrent nonsmall cell lung cancer (NCLC). The study found that the addition of dulanermin to carboplatin and bevacizumab did not improve outcome in unselected patinets with previously untreated advanced or recurrent NSCLC (en)
|
Title
| - Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
- Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer (en)
|
skos:prefLabel
| - Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
- Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer (en)
|
skos:notation
| - RIV/00064211:_____/11:#0000101!RIV12-MZ0-00064211
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00064211:_____/11:#0000101
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - randomised phase II study; dulanermin; combination; paclitaxel; carboplatin; bevacizumab; advanced; non-small cell lung cancer (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Journal of Clinical Oncology
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Zatloukal, Petr
- Pan, Y.
- Albert, I.
- Amler, L.
- Ashkenazi, A.
- Baker, N.
- Blackhall, F.
- Hei, Y. J.
- Juhász, E.
- Kozielski, J.
- Márk, Z.
- Pujol, J. L.
- Smethurst, D.
- Soria, JC
- Stern, H.
- Szima, B.
|
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| |
is http://linked.open...avai/riv/vysledek
of | |